(ICF)- IMMPROVE: Immune Memory and Mechanisms of Protection from Vaccines
Lead Research Organisation:
UNIVERSITY OF OXFORD
Department Name: Paediatrics
Abstract
The COVID-19 pandemic saw the rapid development and deployment of a range of vaccine platforms. While essential to protect against severe disease, these vaccine platforms need further optimisation to provide long-term and local protection against infection including future variants. This vaccine optimisation requires an improved understanding of how a protective immune response is induced, how it is maintained, and the role of immunity in the nose and the lungs.
Building on the experience our consortium amassed during the COVID-19 pandemic, we will answer some of the key outstanding questions in the field:
1.MEMORY We will delineate the mechanisms which influence the duration of protective immune responses. Improving understanding of immune memory is critical for the development and deployment of future vaccines with long-lasting protection against both pandemic and endemic pathogens.
2. LOCATION We will determine the role of the immune response in the airways, as the entry route for virus, in protection against infection. The aim is to understand if nasally administered vaccines can stop infection and onward transmission, as well as protect against severe disease.
3. PROTECTION We will define which aspects of the immune response protect against disease and how to maximise these responses. This will enable vaccine developers to focus on new vaccines that deliver improved protection.
4. DATA There exist large datasets from clinical trials and real-world studies that, if combined with the data from this programme, would generate a unique resource for understanding how vaccines work. To achieve this, we will develop an integrated data structure and open-source computational tools to integrate disparate data and maximise data usefulness.
5.IMPACT We will bolster pandemic preparedness by the training and empowerment of future leaders in vaccine development and engaging public understanding of the need for vaccines.
Targeting these questions will lead to increased capability for rational, immunologically-driven vaccine development and uptake.
Building on the experience our consortium amassed during the COVID-19 pandemic, we will answer some of the key outstanding questions in the field:
1.MEMORY We will delineate the mechanisms which influence the duration of protective immune responses. Improving understanding of immune memory is critical for the development and deployment of future vaccines with long-lasting protection against both pandemic and endemic pathogens.
2. LOCATION We will determine the role of the immune response in the airways, as the entry route for virus, in protection against infection. The aim is to understand if nasally administered vaccines can stop infection and onward transmission, as well as protect against severe disease.
3. PROTECTION We will define which aspects of the immune response protect against disease and how to maximise these responses. This will enable vaccine developers to focus on new vaccines that deliver improved protection.
4. DATA There exist large datasets from clinical trials and real-world studies that, if combined with the data from this programme, would generate a unique resource for understanding how vaccines work. To achieve this, we will develop an integrated data structure and open-source computational tools to integrate disparate data and maximise data usefulness.
5.IMPACT We will bolster pandemic preparedness by the training and empowerment of future leaders in vaccine development and engaging public understanding of the need for vaccines.
Targeting these questions will lead to increased capability for rational, immunologically-driven vaccine development and uptake.
Technical Summary
The contribution of the expert scientists in this consortium, their accumulated knowledge, unique facilities and proven methodologies places this consortium at the epicentre of enabling rapid control not only of SARS-CoV-2 but other potential pandemics. Through mechanistic immunology, we will deliver a new tool-kit for pandemic responsiveness, we will be ideally positioned for future vaccine design.
Harnessing the current and future expertise of this consortium, its PIs, future-leaders, data-sets, public and patient involvement and engagement experts, we will consolidate learnings from COVID-19 and enable outbreak and pandemic readiness to meet the challenges of changing infection patterns in the 21st century.
The core objectives of the consortium are:
1. To understand the immune mechanisms required for long-lived and broad protection against SARS-CoV-2, and how to effectively induce these responses through vaccination.
2. To understand the duality of systemic and local immunity against SARS-CoV-2, their corresponding roles in protection against disease and infection/transmission, and how to replicate these advantages through vaccination.
3. To define mechanistic correlates of protection, empowering next-generation pan-coronavirus vaccine development.
4. To build resilient long-term capacity in pandemic preparedness via bolstering the global network of scientists; training, developing and empowering early-career researchers in vaccinology and vaccine design; and augmenting the biosciences capability for vaccine development and rapid response to emergent pathogens.
5. Build upon the strong links of the consortium with the public, extend the network of public engagement and involvement to early-career researchers, and act as a bidirectional bridge between the public and vaccine developers / policy makers to aid support and uptake of vaccination.
Harnessing the current and future expertise of this consortium, its PIs, future-leaders, data-sets, public and patient involvement and engagement experts, we will consolidate learnings from COVID-19 and enable outbreak and pandemic readiness to meet the challenges of changing infection patterns in the 21st century.
The core objectives of the consortium are:
1. To understand the immune mechanisms required for long-lived and broad protection against SARS-CoV-2, and how to effectively induce these responses through vaccination.
2. To understand the duality of systemic and local immunity against SARS-CoV-2, their corresponding roles in protection against disease and infection/transmission, and how to replicate these advantages through vaccination.
3. To define mechanistic correlates of protection, empowering next-generation pan-coronavirus vaccine development.
4. To build resilient long-term capacity in pandemic preparedness via bolstering the global network of scientists; training, developing and empowering early-career researchers in vaccinology and vaccine design; and augmenting the biosciences capability for vaccine development and rapid response to emergent pathogens.
5. Build upon the strong links of the consortium with the public, extend the network of public engagement and involvement to early-career researchers, and act as a bidirectional bridge between the public and vaccine developers / policy makers to aid support and uptake of vaccination.
Organisations
- UNIVERSITY OF OXFORD (Lead Research Organisation, Project Partner)
- University of Cambridge (Collaboration)
- University of Sheffield (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- Newcastle University (Collaboration)
- University College London (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- University Libre Bruxelles (Université Libre de Bruxelles ULB) (Collaboration)
- UNIVERSITY OF BIRMINGHAM (Collaboration)
- University of Glasgow (Collaboration)
- Mount Sinai Hospital (Collaboration)
- University of Liverpool (Collaboration)
- Sanofi (International) (Project Partner)
- Moderna Therapeutics Inc (Project Partner)
- AstraZeneca (Global) (Project Partner)
- Janssen Vaccines & Prevention (Project Partner)
- UNIVERSITY COLLEGE LONDON (Project Partner)
Publications
Al-Diwani A
(2024)
Multi-site Ultrasound-guided Fine Needle Aspiration to Study Cells and Soluble Factors From Human Lymph Nodes.
in Current protocols
Amini A
(2025)
MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines.
in Science immunology
Belij-Rammerstorfer S
(2025)
Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222)
in eBioMedicine
Bissett C
(2026)
Heterologous mucosal vaccine boosting enhances mucosal and systemic immunity by distinct mechanisms.
in The Journal of experimental medicine
Burton O
(2025)
Introducing the Dish Soap Protocol: A Unified Approach for Multi-Modal Intracellular Staining
in Current Protocols
Burton O
(2025)
Optimization of the Blocking and Signal Preservation Protocol in High-Parameter Flow Cytometry
in Current Protocols
Copland E
(2024)
Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England.
in Nature communications
Dallan B
(2024)
Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19.
in Nature aging
| Title | Dangerous matter |
| Description | A chamber opera about how immune memory was discovered and the story of variation. |
| Type Of Art | Performance (Music, Dance, Drama, etc) |
| Year Produced | 2025 |
| Impact | Premier in Manchester RNCM. Feedback was very positive from audience which included schools and scientists. A discussion of the opera also took place at History of Science Museum Oxford |
| URL | https://www.immunology.ox.ac.uk/news/2018dangerous-matter2019-a-new-opera-on-vaccine-science-memory-... |
| Description | ECR training from IMMPROVE via BSI |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Monthly Scientific meetings to share best practice and new findings |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Mechanism of early tissue response in vaccination with lipid encapsulated non-amplifying mRNA (MechRNA) |
| Amount | £1,905,588 (GBP) |
| Funding ID | 678 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2025 |
| End | 02/2028 |
| Title | CRISPR methodology |
| Description | • To enable high-throughput screening of genes critical to the induction of cellular and humoral immunity by vaccination, we have implemented an in vivo CRISPR screening protocol. This protocol uses CRISPR/Cas9 gene editing of haematopoietic progenitor cells, which allows for the genetic alterations to be made at a developmental stage prior to B and T cell development, thereby bypassing major technical complications of working with mature lymphocytes. This protocol will be used to identify positive and negative regulators of adaptive immunity to inform potentially targetable pathways in next generation vaccine design. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2025 |
| Provided To Others? | No |
| Impact | This methodology has been published elsewhere |
| Title | Cell2TCR identifies activated antigen-responding T?cells based on a gene expression signature and clusters these into clonotype groups |
| Description | Cell2TCR is a tool for inference of T cell receptor (TCR) motifs. A TCR motif describes a group of TCRs with sufficient sequence similarity to likely recognise a common epitope. |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2024 |
| Provided To Others? | Yes |
| Impact | Our new computational pipeline Cell2TCR identifies activated antigen-responding T cells based on a gene expression signature and clusters these into clonotype groups and motifs. Overall, our detailed time series data can serve as a Rosetta stone for epithelial and immune cell responses and reveals early dynamic responses associated with protection against infection. |
| URL | https://github.com/Teichlab/Cell2TCR |
| Title | Ex vivo Model of Functioning Human Lymph Node Reveals Pivotal Role for Innate Lymphoid Cells and Stromal Populations in Response to Vaccine Adjuvant |
| Description | We describe precision-cut human lymph node (LN) slices as architecturally-preserved, functioning lymphoid tissue model system, and explore early inflammatory responses to a potent vaccine liposomal adjuvant containing a TLR4-agonist and QS21 saponin. Combining scRNA-seq, multiplexed immunofluorescence and secretome analysis, we dissect direct and indirect signalling pathways in both leukocytes and stromal cells to reveal communication networks linking innate and adaptive immunity. Application of molecular inhibitors reveals that secretion of IL 1b, but not IL-18, is TLR4-dependent in human LN. Retaining donor-to-donor immune variation, this ex vivo LN model system enables the study of pathways previously difficult to observe in humans, paving the way towards precision medicine. |
| Type Of Material | Model of mechanisms or symptoms - in vitro |
| Year Produced | 2024 |
| Provided To Others? | Yes |
| Impact | The ex vivo human LN slice approach described here offers a versatile platform for studying mode of action and early cell signalling responses, and could be applied to a variety of compounds, from novel small molecule drugs to a range of immunostimulants and existing therapeutics. Cumulatively, evaluating responses to immune or inflammatory perturbation on a per donor basis, and building our understanding of the principles and nuances of the underlying mechanisms, could pave the way for the rational design of vaccines and drugs towards achieving precision medicine. |
| URL | https://www.biorxiv.org/content/10.1101/2024.08.21.608943v1.full.pdf |
| Title | Immproved identification of immune correlates after immunisation |
| Description | • The IMMPROVE flow panel, developed by the IMMPROVE consortium, assesses 77 immune markers simultaneously, a 50% increase over the largest published immune phenotyping panel. It has numerous advantages, for example, optimized detection of transcription factors, sensitive detection and deep phenotyping of antigen-specific T and B cells, as well as comprehensive identification of circulating immune cell types. • The panel has been developed across the consortium with 10-20/meeting and 60-70 individuals feeding back from the mailing list |
| Type Of Material | Biological samples |
| Year Produced | 2025 |
| Provided To Others? | Yes |
| Impact | • co-ordinated staining across labs and clinical trails - findings and panel will be shared in an upcoming publication |
| Title | Multi-site Ultrasound-guided Fine Needle Aspiration to Study Cells and Soluble Factors From Human Lymph Nodes |
| Description | This minimally invasive technique allows collection of both immune cells and cell-free material that are relevant to both neuroimmune diseases and basic lymphatic functions. Downstream use of cellular material can include multiplexed flow cytometry, single-cell transcriptome sequencing (RNA-seq), and B cell cultures. The cell-free supernatant can be used for proteomics or other similar 'omics approaches. This unit describes collection of samples by FNA as well as processing and storage of samples for downstream assays. |
| Type Of Material | Model of mechanisms or symptoms - human |
| Year Produced | 2024 |
| Provided To Others? | Yes |
| Impact | We describe the application of FNA under ultrasound guidance to sample human LNs, with cervical LN sampling used as an exemplar. FNA is a commonplace physical investigation in various medical contexts, including pathology involving LNs, but driven by advances in downstream '-omic' technologies, the technique has in recent years been shown to be highly adaptable to healthy LNs in a clinical research context and to address the temporal and anatomical considerations discussed above. |
| URL | https://currentprotocols.onlinelibrary.wiley.com/doi/10.1002/cpz1.70063 |
| Title | Pump-priming access to ECR to facilitate next generation of researchers |
| Description | • As part of the IMMPROVE consortium we had an open call to access funding, available to ECRs, to generate data from three work-streams streams - High dimensional flow cytometry, Olink proteomics, and In vivo murine SARS-CoV-2 challenge models • 21 applications were received from final year PhD students to post-doctoral researchers. All applicants worked with lead researchers within each stream to develop their proposal before submission. Of the 21 that applied, 13 were judged relevant and were funded to the tune of £154,000. |
| Type Of Material | Biological samples |
| Year Produced | 2025 |
| Provided To Others? | No |
| Impact | these projects will be delivered in the near future and readouts reported back |
| Title | Ex vivo Model of Functioning Human Lymph Node Reveals Pivotal Role for Innate Lymphoid Cells and Stromal Populations in Response to Vaccine Adjuvant |
| Description | We describe precision-cut human lymph node (LN) slices as architecturally-preserved, functioning lymphoid tissue model system, and explore early inflammatory responses to a potent vaccine liposomal adjuvant containing a TLR4-agonist and QS21 saponin. Combining scRNA-seq, multiplexed immunofluorescence and secretome analysis, we dissect direct and indirect signalling pathways in both leukocytes and stromal cells to reveal communication networks linking innate and adaptive immunity. Application of molecular inhibitors reveals that secretion of IL 1b, but not IL-18, is TLR4-dependent in human LN. Retaining donor-to-donor immune variation, this ex vivo LN model system enables the study of pathways previously difficult to observe in humans, paving the way towards precision medicine. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2024 |
| Provided To Others? | Yes |
| Impact | We describe precision-cut human lymph node (LN) slices as architecturally-preserved, functioning lymphoid tissue model system, and explore early inflammatory responses to a potent vaccine liposomal adjuvant containing a TLR4-agonist and QS21 saponin. Combining scRNA-seq, multiplexed immunofluorescence and secretome analysis, we dissect direct and indirect signalling pathways in both leukocytes and stromal cells to reveal communication networks linking innate and adaptive immunity. Application of molecular inhibitors reveals that secretion of IL 1b, but not IL-18, is TLR4-dependent in human LN. Retaining donor-to-donor immune variation, this ex vivo LN model system enables the study of pathways previously difficult to observe in humans, paving the way towards precision medicine. |
| URL | https://www.biorxiv.org/content/10.1101/2024.08.21.608943v1.full.pdf |
| Title | Human SARS-CoV-2 challenge uncovers local and systemic response dynamics |
| Description | The COVID-19 pandemic is an ongoing global health threat, yet our understanding of the dynamics of early cellular responses to this disease remains limited1. Here in our SARS-CoV-2 human challenge study, we used single-cell multi-omics profiling of nasopharyngeal swabs and blood to temporally resolve abortive, transient and sustained infections in seronegative individuals challenged with pre-Alpha SARS-CoV-2. Our analyses revealed rapid changes in cell-type proportions and dozens of highly dynamic cellular response states in epithelial and immune cells associated with specific time points and infection status. We observed that the interferon response in blood preceded the nasopharyngeal response. Moreover, nasopharyngeal immune infiltration occurred early in samples from individuals with only transient infection and later in samples from individuals with sustained infection. High expression of HLA-DQA2 before inoculation was associated with preventing sustained infection. Ciliated cells showed multiple immune responses and were most permissive for viral replication, whereas nasopharyngeal T cells and macrophages were infected non-productively. We resolved 54 T cell states, including acutely activated T cells that clonally expanded while carrying convergent SARS-CoV-2 motifs. Our new computational pipeline Cell2TCR identifies activated antigen-responding T cells based on a gene expression signature and clusters these into clonotype groups and motifs. Overall, our detailed time series data can serve as a Rosetta stone for epithelial and immune cell responses and reveals early dynamic responses associated with protection against infection. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2024 |
| Provided To Others? | Yes |
| Impact | Our new computational pipeline Cell2TCR identifies activated antigen-responding T cells based on a gene expression signature and clusters these into clonotype groups and motifs. Overall, our detailed time series data can serve as a Rosetta stone for epithelial and immune cell responses and reveals early dynamic responses associated with protection against SARS-CoV-2 infection. |
| URL | https://www.nature.com/articles/s41586-024-07575-x#citeas |
| Title | IMMPROVE data warehouse and catalogue platform |
| Description | A consortium-wide catalogue of available datasets has been developed using the Invenio RDM web-based database platform (https://inveniosoftware.org/products/rdm/). This is linked through to the Mauro Data Mapper (https://maurodatamapper.github.io/) which provides a searchable web interface documenting the data types of the fields, their descriptions, valid dictionaries and other pertinent metadata. Finally, this links to an implementation of the cBioPortal platform (https://www.cbioportal.org/) which allows consortium members to explore the datasets at an aggregated level. This supports rapid discovery of applicability to specific research questions without disclosing the dataset itself, thereby supporting information governance and GDPR requirements. |
| Type Of Material | Computer model/algorithm |
| Year Produced | 2025 |
| Provided To Others? | No |
| Impact | This platform has allowed consortium members to explore diverse datasets in an accessible manner without the need for computational skills. This is helping to identify new ways of using the consortium's datasets, along with other public datasets to drive outputs from IMMPROVE. |
| Description | Collaboration with the MUSICC Consortium |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Our work in the MUSICC Consortium involves conducting controlled human infection studies, using intranasal challenge with the SARS-CoV-2 Omicron BA.5 variant and a new SARS-CoV-2 variant (strain TBD). Samples collected during these studies will be used in characterising the immune mechanisms associated with SARS-CoV-2 infection and identifying correlates of protection. Our work includes assay development and selecting candidate assays aimed at evaluating mucosal immunity (e.g assays for mucosal proteomics profiling). In addition, the spectral flow cytometry panels developed as part of the IMMPROVE WP5 project will be used in these studies. |
| Collaborator Contribution | We work closely with partners from the MUSICC Consortium to advance the development, standardisation, harmonisation, and qualification of immune assays, with a special focus on characterising mucosal immune responses. We also benefit from reagent sharing. |
| Impact | We are in the process of developing standard operating procedures and will also be drafting methodology papers outlining our work in assay development and standardisation. |
| Start Year | 2024 |
| Description | G2P2/ProVac Consortium |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | As IMMPROVE, we regularly communicate with G2P2 and ProVac. We approach this by inviting the other consortium members to present at our monthly meetings and also extend an invite to both G2P2 and ProVac to our annual meeting. These meetings provided a platform to share progress on ongoing research activities and promoting knowledge sharing and interdisciplinary collaboration. |
| Collaborator Contribution | Knowledge exchange and integration of diverse expertise. |
| Impact | Generation of significant research findings, interdisciplinary collaboration and knowledge exchange |
| Start Year | 2024 |
| Description | MUSICC Consortium (CEPI/EU funded) |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Work aligned with MUSICC Consortium. |
| Collaborator Contribution | SARS-CoV-2 Delta challenge study (breakthrough infection model). Seroscreening required to identify participants with low pre-existing neutralising antibodies. |
| Impact | Identified potential correlates of protection (univariate analyses due to small sample size): o Serum neutralising antibodies o ACE2 inhibition o Anti-N binding IgG o Nasal anti-spike IgA o N-specific T cells (borderline significance) |
| Start Year | 2025 |
| Description | Mucosal Study |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | - Development of SOPs for nasal cell immunophenotyping - Development of methodology for the detection of antigen-specific T responses in the upper and lower airway mucosa - Development of methodology for the detection of antigen-specific B cell responses in the upper and lower airway mucosa |
| Collaborator Contribution | Characterisation of SARS-CoV-2 humoral and cellular responses in the lower airways of infected and/or vaccinated individuals in Malawi |
| Impact | Both Malawi/ UK study are running or ready to start, so no publications/ data uploaded to repositories yet. |
| Start Year | 2024 |
| Description | PITCH Consortium |
| Organisation | Newcastle University |
| Country | United Kingdom |
| PI Contribution | 1. Used longitudinal samples from extensively characterised PITCH cohort to establish how phenotype of T cell memory evolves with repeated exposure 2. Provided healthy control samples for comparison of mRNA vs ChAdOx in HSCT recipients and healthy controls |
| Collaborator Contribution | Knowledge exchange, sample and reagent sharing |
| Impact | https://onlinelibrary.wiley.com/doi/10.1111/bjh.19874 - also used in evidence submission to JCVI on dosing interval in HSCT revaccination regimes in UK Greenbook. |
| Start Year | 2024 |
| Description | PITCH Consortium |
| Organisation | University of Birmingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | 1. Used longitudinal samples from extensively characterised PITCH cohort to establish how phenotype of T cell memory evolves with repeated exposure 2. Provided healthy control samples for comparison of mRNA vs ChAdOx in HSCT recipients and healthy controls |
| Collaborator Contribution | Knowledge exchange, sample and reagent sharing |
| Impact | https://onlinelibrary.wiley.com/doi/10.1111/bjh.19874 - also used in evidence submission to JCVI on dosing interval in HSCT revaccination regimes in UK Greenbook. |
| Start Year | 2024 |
| Description | PITCH Consortium |
| Organisation | University of Liverpool |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | 1. Used longitudinal samples from extensively characterised PITCH cohort to establish how phenotype of T cell memory evolves with repeated exposure 2. Provided healthy control samples for comparison of mRNA vs ChAdOx in HSCT recipients and healthy controls |
| Collaborator Contribution | Knowledge exchange, sample and reagent sharing |
| Impact | https://onlinelibrary.wiley.com/doi/10.1111/bjh.19874 - also used in evidence submission to JCVI on dosing interval in HSCT revaccination regimes in UK Greenbook. |
| Start Year | 2024 |
| Description | PITCH Consortium |
| Organisation | University of Sheffield |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | 1. Used longitudinal samples from extensively characterised PITCH cohort to establish how phenotype of T cell memory evolves with repeated exposure 2. Provided healthy control samples for comparison of mRNA vs ChAdOx in HSCT recipients and healthy controls |
| Collaborator Contribution | Knowledge exchange, sample and reagent sharing |
| Impact | https://onlinelibrary.wiley.com/doi/10.1111/bjh.19874 - also used in evidence submission to JCVI on dosing interval in HSCT revaccination regimes in UK Greenbook. |
| Start Year | 2024 |
| Description | Scientific Advisory Board (SAB) |
| Organisation | Mount Sinai Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Our team has contributed to the SAB collaboration by facilitating regular scientific meetings, coordinating stakeholder engagement, and ensuring effective communication between partners. |
| Collaborator Contribution | The Scientific Advisory Board to the IMMPROVE Consortium has provided and continues to provide key scientific feedback on optimal approaches to meet our proposed outcomes and our ongoing activities in both the short and long-term. |
| Impact | The SAB made significant contributions at annual scientific meeting recently held in January 2025 and we will be implementing the suggestions and recommendations made in the areas of Early Career Research (ECR) Training and Support, Future Research directions, our ongoing the age-based cohort studies and further funding. |
| Start Year | 2024 |
| Description | Scientific Advisory Board (SAB) |
| Organisation | University Libre Bruxelles (Université Libre de Bruxelles ULB) |
| Department | Institute for Medical Immunology |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | Our team has contributed to the SAB collaboration by facilitating regular scientific meetings, coordinating stakeholder engagement, and ensuring effective communication between partners. |
| Collaborator Contribution | The Scientific Advisory Board to the IMMPROVE Consortium has provided and continues to provide key scientific feedback on optimal approaches to meet our proposed outcomes and our ongoing activities in both the short and long-term. |
| Impact | The SAB made significant contributions at annual scientific meeting recently held in January 2025 and we will be implementing the suggestions and recommendations made in the areas of Early Career Research (ECR) Training and Support, Future Research directions, our ongoing the age-based cohort studies and further funding. |
| Start Year | 2024 |
| Description | Scientific Advisory Board (SAB) |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Our team has contributed to the SAB collaboration by facilitating regular scientific meetings, coordinating stakeholder engagement, and ensuring effective communication between partners. |
| Collaborator Contribution | The Scientific Advisory Board to the IMMPROVE Consortium has provided and continues to provide key scientific feedback on optimal approaches to meet our proposed outcomes and our ongoing activities in both the short and long-term. |
| Impact | The SAB made significant contributions at annual scientific meeting recently held in January 2025 and we will be implementing the suggestions and recommendations made in the areas of Early Career Research (ECR) Training and Support, Future Research directions, our ongoing the age-based cohort studies and further funding. |
| Start Year | 2024 |
| Description | Scientific Advisory Board (SAB) |
| Organisation | University of Oxford |
| Department | Nuffield Department of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Our team has contributed to the SAB collaboration by facilitating regular scientific meetings, coordinating stakeholder engagement, and ensuring effective communication between partners. |
| Collaborator Contribution | The Scientific Advisory Board to the IMMPROVE Consortium has provided and continues to provide key scientific feedback on optimal approaches to meet our proposed outcomes and our ongoing activities in both the short and long-term. |
| Impact | The SAB made significant contributions at annual scientific meeting recently held in January 2025 and we will be implementing the suggestions and recommendations made in the areas of Early Career Research (ECR) Training and Support, Future Research directions, our ongoing the age-based cohort studies and further funding. |
| Start Year | 2024 |
| Description | Networking event for recruiting peer researchers |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | About 50 ethnic minority community members attended a Health Research engagement event to learn about community researchers and we discussed how to participate as peer researchers for social science research. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Pop-up event at Festival of Tomorrow |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | We held a pop up event with NHS and community partners about 'The Future of Health' and engaged with about 60 people. |
| Year(s) Of Engagement Activity | 2025 |
| Description | Stand at IF Oxford Science + Ideas Festival |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | We held a stall at a science fair that about 200 people participated in engagement activities aimed at families about vaccines and the immune system. We conducted some light touch evaluations that indicated understandings improved after taking part. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Thanks for the memories |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Interaction with Royal College of Music to start composition on T cell memory and immune protection |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.immunology.ox.ac.uk/about/public-engagement/thanks-for-the-memories-t4tm |